Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2022 16:01 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q1 2022 Financial Results and Business Update

Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled,...
May 03, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
May 03, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date Seventeen of 18 patients with follow-up...
March 29, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) --...
March 23, 2022 06:00 ET | Source: Market Study Report

Asia Pacific ultrasonic sensor market size to experience remunerative growth trends through 2027

Pune, India, March 23, 2022 (GLOBE NEWSWIRE) -- According to MarketStudyReport, Asia Pacific ultrasonic sensor market size is projected to amass a valuation of USD 2.5 billion by the year 2027,...
December 27, 2021 08:30 ET | Source: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart Attack

SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life...
December 06, 2021 13:49 ET | Source: Adagene, Inc.

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
December 06, 2021 06:30 ET | Source: Adagene, Inc.

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
December 01, 2021 09:55 ET | Source: SIGA Technologies Inc.

SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that...
November 10, 2021 06:07 ET | Source: Meticulous Market Research Pvt. Ltd.

Pharmaceutical Contract Development and Manufacturing Market Worth $134.2 billion by 2027 – Exclusive Report by Meticulous Research®

Redding, California, Nov. 10, 2021 (GLOBE NEWSWIRE) -- According to a new market research report “Pharmaceutical Contract Development and Manufacturing Market by Service [Pharmaceutical Contract...